7,626.92

+46.85

+0.62%

52,284.12

+513.81

+0.99%

25,629.40

+192.40

+0.76%

2,838.45

+26.60

+0.95%

4.8920

-0.0370

-0.75%

18.73

-0.69

-3.55%

3,975.50

+76.60

+1.96%

77,405.73

-614.27

-0.79%

Crude Oil Dec 26

96.87

-7.25

-6.96%

US Private Equity

10,850.63

-82.20

-0.75%

HKSE - Delayed Quote HKD

InnoCare Pharma Limited (9969.HK)

11.250 0.000 (0.00%)

At close: 4:08:14 PM GMT+8

Loading Chart for 9969.HK

Chart Range Bar

Interval:

In partnership with ChartIQ

InnoCare Announces First Subject Dosed in Clinical Trial of TL1A/IL-23p19 Bispecific Antibody ICP-B161 in China

InnoCare Announces First Subject Dosed in Clinical Trial of TL1A/IL-23p19 Bispecific Antibody ICP-B161 in China

Latest Data of Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2026

Latest Data of Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2026

InnoCare Pharma (SEHK:9969) Stock Shrugs Off Q3 Earnings Turnaround

InnoCare Pharma (SEHK:9969) Stock Shrugs Off Q3 Earnings Turnaround

InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization

InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization

Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology

Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology

$InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China$

InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

Is InnoCare Pharma (SEHK:9969) Undervalued On Its Eli Lilly Deal?

Is InnoCare Pharma (SEHK:9969) Undervalued On Its Eli Lilly Deal?

InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines

InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines

InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China

InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China

InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

Mobilize your Website

View Site in Mobile | Classic

Share by: